Table 1 Patient characteristics – aggressive B-cell lymphoma.
Age (median, min, max) | 63 years (17, 78) | |
|---|---|---|
Sex | Men | 60 (65%) |
Women | 33 (35%) | |
Diagnosis | DLBCL | 61 (66%) |
High grade B-cell lymphoma | 9 (10%) | |
Transformed follicular lymphoma | 13 (14%) | |
Primary mediastinal large B-cell lymphoma | 4 (4%) | |
Other aggressive B-cell lymphomas | 6 (7%) | |
Treatment line | 2 | 12 (13%) |
3 | 45 (48%) | |
4 | 24 (26%) | |
>4 | 12 (13%) | |
Recurrence patterns | Primary refractory disease | 34 (37%) |
Recurrence <12 months after stopping treatment | 25 (27%) | |
Recurrence ≥12 months after discontinuation of treatment | 34 (37%) | |
CNS involvement at relapse | 10 (11%) | |
Year of CAR-T infusion | 2019 | 1 |
2020 | 8 | |
2021 | 23 | |
2022 | 31 | |
2023 | 29 | |
2024 | 1 | |
Cytokine release syndrome (CRS) Maximum grade | 0 | 5 (5%) |
1 | 42 (46%) | |
2 | 44 (48%) | |
3 | 1 (1%) | |
4 | 0 | |
Immune effector-cell associated neurotoxicity syndrome (ICANS) Maximum grade | 0 | 52 (56%) |
1 | 11 (12%) | |
2 | 15 (16%) | |
3 | 8 (9%) | |
4 | 6 (7%) | |
